Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472501 | 0.78 | HDAC3 (0.38) | L3MBTL1NPC1RAB9APOLBMAPT | |
| SCHEMBL6472291 | 0.76 | KMT2A (0.40) | L3MBTL1KDM4EKMT2ANPC1RAB9A | |
| SCHEMBL15881328 | 0.74 | L3MBTL1 (0.55) | L3MBTL1KDM4EKMT2ANPC1RAB9A | |
| SCHEMBL14298343 | 0.73 | L3MBTL1 (0.54) | L3MBTL1KDM4EKMT2ANPC1RAB9A | |
| SCHEMBL6719477 | 0.71 | MAPT (0.50) | KDM4ENPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL29141778 | 0.70 | NPC1 (0.55) | L3MBTL1KDM4EKMT2ANPC1RAB9A | |
| SCHEMBL19699460 | 0.70 | L3MBTL1 (0.51) | L3MBTL1KDM4EKMT2ANPC1RAB9A | |
| SCHEMBL29155745 | 0.70 | POLB (0.64) | L3MBTL1KDM4EKMT2ANPC1RAB9A | |
| SCHEMBL6360506 | 0.69 | KDM4E (0.52) | L3MBTL1KDM4EKMT2ANPC1RAB9A | |
| SCHEMBL4774475 | 0.69 | L3MBTL1 (0.50) | L3MBTL1KDM4EKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | L3MBTL1 3949/4885KDM4E 1190/4885KMT2A 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.